{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:15:10Z","timestamp":1791951310776,"version":"4.3.4"},"reference-count":22,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:00:00Z","timestamp":1682467200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>The North Star ambulatory assessment (NSAA) is a functional motor outcome measure in Duchenne muscular dystrophy (DMD), widely used in clinical trials and natural history studies, as well as in clinical practice. However, little has been reported on the minimal clinically important difference (MCID) of the NSAA. The lack of established MCID estimates for NSAA presents challenges in interpreting the significance of the results of this outcome measure in clinical trials, natural history studies and clinical practice. Combining statistical approaches and patient perspectives, this study estimated MCID for NSAA using distribution-based estimates of 1\/3 standard deviation (SD) and standard error of measurement (SEM), an anchor-based approach, with six-minute walk distance (6MWD) as the anchor, and evaluation of patient and parent perception using participant-tailored questionnaires. The MCID for NSAA in boys with DMD aged 7 to 10 years based on 1\/3 SD ranged from 2.3\u20132.9 points, and that on SEM ranged from 2.9\u20133.5 points. Anchored on the 6MWD, the MCID for NSAA was estimated as 3.5 points. When the impact on functional abilities was considered using participant response questionnaires, patients and parent perceived a complete loss of function in a single item or deterioration of function in one to two items of the assessment as an important change. Our study examines MCID estimates for total NSAA scores using multiple approaches, including the impact of patient and parent perspective on within scale changes in items based on complete loss of function and deterioration of function, and provides new insight on evaluation of differences in these widely used outcome measure in DMD.<\/jats:p>","DOI":"10.1371\/journal.pone.0283669","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T13:30:37Z","timestamp":1682515837000},"page":"e0283669","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":38,"title":["Determining minimal clinically important differences in the North Star Ambulatory Assessment (NSAA) for patients with Duchenne muscular dystrophy"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3022-4307","authenticated-orcid":true,"given":"Vandana","family":"Ayyar Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline M.","family":"Pitchforth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Domingos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Ridout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Iodice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Rye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Chesshyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Wolfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Selby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Mayhew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena S.","family":"Mazzone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Ricotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Hogrel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5892-5143","authenticated-orcid":true,"given":"Erik H.","family":"Niks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imelda","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Servais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9046-3540","authenticated-orcid":true,"given":"Volker","family":"Straub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan Y.","family":"Manzur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Muntoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the iMDEX Consortium and the U.K. NorthStar Clinical Network","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,4,26]]},"reference":[{"issue":"10213","key":"pone.0283669.ref001","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1016\/S0140-6736(19)32910-1","article-title":"Muscular dystrophies","volume":"394","author":"E Mercuri","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"pone.0283669.ref002","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/ejhg.2012.301","article-title":"Newborn bloodspot screening for Duchenne muscular dystrophy: 21 years experience in Wales (UK)","volume":"21","author":"SJ Moat","year":"2013","journal-title":"Eur J Hum Genet"},{"issue":"4","key":"pone.0283669.ref003","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/phar.1909","article-title":"Advances in the Treatment of Duchenne Muscular Dystrophy: New and Emerging Pharmacotherapies","volume":"37","author":"AM Reinig","year":"2017","journal-title":"Pharmacotherapy"},{"issue":"10101","key":"pone.0283669.ref004","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","article-title":"Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"CM McDonald","year":"2017","journal-title":"Lancet"},{"issue":"24","key":"pone.0283669.ref005","doi-asserted-by":"crossref","first-page":"e2146","DOI":"10.1212\/WNL.0000000000005680","article-title":"Eteplirsen treatment for Duchenne muscular dystrophy: Exon skipping and dystrophin production","volume":"90","author":"JS Charleston","year":"2018","journal-title":"Neurology"},{"issue":"2","key":"pone.0283669.ref006","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/pri.520","article-title":"Development of a functional assessment scale for ambulatory boys with Duchenne muscular dystrophy","volume":"17","author":"E Scott","year":"2012","journal-title":"Physiother Res Int"},{"key":"pone.0283669.ref007","unstructured":"Clinical Trials.gov. Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy (Identifer: NCT04281485) 2020 [February 24, 2020]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04281485"},{"issue":"1","key":"pone.0283669.ref008","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.nmd.2017.10.004","article-title":"A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy","volume":"28","author":"N Goemans","year":"2018","journal-title":"Neuromuscul Disord"},{"issue":"8","key":"pone.0283669.ref009","doi-asserted-by":"crossref","first-page":"e866","DOI":"10.1212\/WNL.0000000000006950","article-title":"Cardiac and skeletal muscle effects in the randomized HOPE-Duchenne trial","volume":"92","author":"M Taylor","year":"2019","journal-title":"Neurology"},{"issue":"6","key":"pone.0283669.ref010","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1136\/jnnp-2012-303902","article-title":"Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy","volume":"84","author":"V Ricotti","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"pone.0283669.ref011","doi-asserted-by":"crossref","first-page":"e0221097","DOI":"10.1371\/journal.pone.0221097","article-title":"Categorising trajectories and individual item changes of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy","volume":"14","author":"UK NorthStar Network","year":"2019","journal-title":"PLoS One"},{"issue":"4","key":"pone.0283669.ref012","first-page":"407","article-title":"Measurement of health status. Ascertaining the minimal clinically important difference","volume":"10","author":"R Jaeschke","year":"1989","journal-title":"Control Clin Trials"},{"issue":"5","key":"pone.0283669.ref013","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.spinee.2007.01.008","article-title":"Understanding the minimum clinically important difference: a review of concepts and methods","volume":"7","author":"AG Copay","year":"2007","journal-title":"Spine J"},{"issue":"2","key":"pone.0283669.ref014","first-page":"452","article-title":"Minimal clinically important difference module: summary, recommendations, and research agenda","volume":"28","author":"G Wells","year":"2001","journal-title":"J Rheumatol"},{"issue":"1","key":"pone.0283669.ref015","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1081\/COPD-200050508","article-title":"Bridging the gap: using triangulation methodology to estimate minimal clinically important differences (MCIDs)","volume":"2","author":"NK Leidy","year":"2005","journal-title":"COPD"},{"issue":"11","key":"pone.0283669.ref016","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1111\/dmcn.12220","article-title":"Detecting meaningful change using the North Star Ambulatory Assessment in Duchenne muscular dystrophy","volume":"55","author":"AG Mayhew","year":"2013","journal-title":"Dev Med Child Neurol"},{"issue":"3","key":"pone.0283669.ref017","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/mus.23905","article-title":"The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study","volume":"48","author":"CM McDonald","year":"2013","journal-title":"Muscle Nerve"},{"issue":"2","key":"pone.0283669.ref018","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1177\/0163278705275340","article-title":"Combining Distribution- and Anchor-Based Approaches to Determine Minimally Important Differences: The FACIT Experience","volume":"28","author":"KJ Yost","year":"2005","journal-title":"Evaluation & the Health Professions"},{"issue":"1","key":"pone.0283669.ref019","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12955-020-01398-w","article-title":"Practical issues encountered while determining Minimal Clinically Important Difference in Patient-Reported Outcomes","volume":"18","author":"P Woaye-Hune","year":"2020","journal-title":"Health Qual Life Outcomes"},{"issue":"9","key":"pone.0283669.ref020","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/S0895-4356(99)00071-2","article-title":"Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life","volume":"52","author":"KW Wyrwich","year":"1999","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"pone.0283669.ref021","first-page":"S130","article-title":"DMD\u2013THERAPY: P.286 In the global phase 3 polarisDMD trial for edasalonexent, standardized outcome measure training produces excellent test-retest variability in NSAA","volume":"30","author":"M. Eagle","year":"2020","journal-title":"Neuromuscular Disorders"},{"issue":"8","key":"pone.0283669.ref022","doi-asserted-by":"crossref","first-page":"e0272858","DOI":"10.1371\/journal.pone.0272858","article-title":"Novel approaches to analysis of the North Star Ambulatory Assessment (NSAA) in Duchenne muscular dystrophy (DMD): Observations from a phase 2 trial","volume":"17","author":"F Muntoni","year":"2022","journal-title":"PLoS One"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0283669","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T13:31:31Z","timestamp":1682515891000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0283669"}},"subtitle":[],"editor":[{"given":"Stephen E","family":"Alway","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,4,26]]},"references-count":22,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0283669","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,26]]}}}